Daily Stock Analysis, CDTX, Cidara Therapeutics Inc, priceseries

Cidara Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
5.19
Close
5.35
High
5.45
Low
5.15
Previous Close
5.20
Daily Price Gain
0.15
YTD High
8.55
YTD High Date
Mar 15, 2018
YTD Low
3.70
YTD Low Date
Apr 16, 2018
YTD Price Change
-1.60
YTD Gain
-23.02%
52 Week High
8.80
52 Week High Date
Oct 25, 2017
52 Week Low
3.70
52 Week Low Date
Apr 16, 2018
52 Week Price Change
-1.35
52 Week Gain
-20.15%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 20. 2017
6.95
Oct 6. 2017
7.69
12 Trading Days
10.67%
Link
LONG
May 22. 2018
4.90
Jun 7. 2018
5.43
11 Trading Days
10.87%
Link
Company Information
Stock Symbol
CDTX
Exchange
NasdaqGM
Company URL
http://www.cidara.com
Company Phone
858-752-6170
CEO
Jeffrey L. Stein
Headquarters
California
Business Address
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001610618
About

Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections. Is portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.